Table 1.
Summary of characteristics, patient demographic details for each study.
| Study | Design | HTO type/UKA model | Number of operation knees | Age (y) | Female/Male | BMI (kg/m2) | OA severtity grade | Follow-up | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Liu 2021 | Retrospective | OWHTO/MB | HTO | 48 | 59.5 ± 3.5 | 32/16 | 28.1 ± 1.8 | K-L grade 2/3 | 3.3 Y | |
| UKA | 49 | 61.2 ± 2.8 | 31/18 | 27.3 ± 2.1 | 3.5 Y | |||||
| Watanabe 2021 | Retrospective | OWHTO/UKA | HTO | 48(46 patients) | 61.3 ± 9.8 | NC | 26.1 ± 3.8 | K–L grade 2/3 | 22.0 M | |
| UKA | 48(44 patients) | 73.8 ± 5.2 | 24.1 ± 2.8 | 22.5 M | ||||||
| Rodkey 2021 | Retrospective | OWHTO/UKA | HTO | 113 | 40 | 12/101 | 29.8 | NC | 5.3 Y | |
| UKA | 270 | 48 | 80/190 | 31.0 | 6.3 Y | |||||
| Lin 2021 | Retrospective | OWHTO/MB | HTO | 53 | 56.0 ± 10.2 | 40/13 | 26.3 ± 3.2 | K–L grade 2/3 | More than 1 y | |
| UKA | 61 | 61.4 ± 4.7 | 46/15 | 26.0 ± 3.1 | ||||||
| Jin 2021 | Retrospective | OWHTO/FB | HTO | 67 | 64.1 ± 4.0 | 67/0 | 25.5 ± 3.1 | K–L grade 3/4 | 16/51 | More than 1 y |
| UKA | 67 | 63.1 ± 4.9 | 65/2 | 25.5 ± 2.8 | 15/52 | |||||
| Zhang 2020 | Retrospective | OWHTO/UKA | HTO | 109 | 51.8 ± 6.9 | 86/23 | 26.4 ± 3.6 | NC | 40.2 ± 13.5 M | |
| UKA | 83 | 53.7 ± 5.2 | 66/17 | 27.7 ± 4.1 | 39.3 ± 11.2 M | |||||
| Hou 2020 | Retrospective | OWHTO/MB | HTO | 30 | NC | NC | NC | NC | NC | |
| UKA | 30 | |||||||||
| Chen 2020 | Retrospective | OWHTO/MB | HTO | 18 | 56.1 ± 6.4 | 13/5 | NC | K–L grade 2/3 | 1.0–2.8 Y | |
| UKA | 20 | 56.1 ± 6.5 | 14/6 | 1.0–3.2 Y | ||||||
| Jacquet 2020 | Retrospective | OWHTO/FB | HTO | 50 | 49.3 ± 3.9 | 22/28 | 26.6 ± 2.6 | NC | 3.7 ± 1.6 Y | |
| UKA | 50 | 50.8 ± 4.4 | 21/29 | 27.1 ± 3.1 | 3.9 ± 1.8 Y | |||||
| Song 2019 | Retrospective | CWHTO/FB | HTO | 60 | 59.7 ± 4.1 | 51/9 | 25.1 ± 3.6 | K–L grade 3/4 | 50/10 | 10.7 ± 5.7 Y |
| UKA | 50 | 60.8 ± 3.9 | 43/7 | 25.3 ± 3.4 | 34/36 | 12.0 ± 7.1 Y | ||||
| Koh 2019 | Retrospective | OWHTO/MB | HTO | 123 | 56.1 ± 5.6 | 104/19 | 25.9 ± 3.2 | AH grade <2/≥2 | 97/26 | 2 Y |
| UKA | 118 | 60.8 ± 4.7 | 98/20 | 25.8 ± 2.9 | 37/81 | 2 Y | ||||
| Kim 2019 | Prospective | OWHTO/MB | HTO | 49 | 56.1 ± 6.2 | 43/6 | 26.6 ± 9.2 | K–L grade 2/3/4 | 9/28/12 | 2 Y |
| UKA | 42 | 63.6 ± 5.5 | 35/7 | 25.3 ± 2.4 | 0/23/19 | 2 Y | ||||
| Ryu 2018 | Retrospective | OWHTO/FB | HTO | 23 | 57.6 ± 6.4 | 22/1 | 27.7 ± 2.9 | NC | 40.0 ± 19.4 M | |
| UKA | 22 | 60.5 ± 3.4 | 19/3 | 25.4 ± 3.6 | 33.1 ± 8.7 M | |||||
| Cho 2018 | Retrospective | OWHTO/ MB | HTO | 20(17 patients) | 58.4 ± 5.5 | 12/8 | 26.5 ± 2.5 | AH grade 2/3 | 18/2 | 48.4 ± 14.3 M |
| UKA | 20(17 patients) | 67.9 ± 9.0 | 19/1 | 26.1 ± 2.6 | 13/7 | 39.7 ± 14.0 M | ||||
| Zhao 2017 | Prospective | OWHTO/UKA | HTO | 36 | 53.91 ± 7.35 | 33/3 | NC | K–L grade 2/3 | 10/26 | 2 Y |
| UKA | 36 | 52.47 ± 8.41 | 31/5 | 11/25 | 2 Y | |||||
| Maxwell 2017 | Retrospective | OWHTO/MB | HTO | 75 | Under 55 | NC | NC | NC | 8.1 Y | |
| UKA | 95 | Under 55 | 6.1 Y | |||||||
| Krych 2017 | Retrospective | OWHTO, CWHTO/MB | HTO | 57 | 42.7 | 16/41 | 31.8 | NC | >2 Y | |
| UKA | 183 | 49.2 | 95/88 | 32.4 | >2 Y | |||||
| Jeon 2017 | Retrospective | OWHTO/FB | HTO | 26 | 56.8 | 22/4 | 26.6 | NC | 34.7 M | |
| UKA | 21 | 60.7 | 17/4 | 26.1 | 34.7 M | |||||
| Petersen 2016 | Retrospective | OWHTO/ MB | HTO | 23 | 58.9 ± 2.8 | 9/14 | 23 | AH grade 1/2/3 | 14/9/0 | >5 Y |
| UKA | 25 | 60.7 ± 2.5 | 16/9 | 25 | 1/20/5 | >5 Y | ||||
| Tuncay 2015 | Retrospective | OWHTO, Demo-HTO/MB | HTO | 93(88 patients) | 51.7, 53.5 | 70/18 | NC | NC | 40.4 M, 30.7 M | |
| UKA | 109(94patients) | 58.7 | 79/15 | 42.5 M | ||||||
| Yim 2013 | Retrospective | OWHTO/FB | HTO | 58 | 58.3 ± 5.4 | 51/7 | NC | NC | 3.6 ± 0.4 Y | |
| UKA | 50 | 60.3 ± 4.5 | 48/2 | 3.7 ± 0.4 Y | ||||||
| Takeuchi 2010 | Retrospective | OWHTO/FB | HTO | 27(24 patients) | 67 ± 7 | 18/6 | NC | AH grade 2/3/4/5 | 11/14/2/0 | 61 ± 10 M |
| UKA | 30(18 patients) | 77 ± 4 | 14/4 | 4/17/8/1 | 84 ± 4 M | |||||
| Borjesson 2005 | Prospective | CWHTO/FB | HTO | 18 | 63 ± 3 | 8/10 | NC | AH grade 1/2/3 | 4/7/7 | 5 Y |
| UKA | 22 | 63 ± 4 | 11/11 | 7/6/9 | 5 Y | |||||
| Stukenborg 2001 | Prospective | CWHTO/FB | HTO | 32(32 patients) | 67(60–79) | 13/19 | NC | AH grade 1/2/3/4/5 | 18/7/1/5/1 | 7–10 Y |
| UKA | 30(28 patients) | 67(60–80) | 22/6 | 11/9/4/6/0 | 7–10 Y | |||||
| Weale 1994 | Retrospective | CWHTO/FB | HTO | 49(45 patients) | 74 | NC | NC | NC | 12–17 Y | |
| UKA | 42(34 patients) | 80 | 12–17 Y | |||||||
| Weidenhielm 1992 | Prospective | CWHTO/FB | HTO | 25 | 63 | 14/11 | NC | AH grade 1/2/3 | 4/14/10 | 1 Y |
| UKA | 28 | 63 | 14/14 | 3/10/12 | 1 Y | |||||
| Ivarsson 1991 | Retrospective | CWHTO/FB | HTO | 10 | 62 ± 4 | 6/4 | NC | AH grade 1/2/3 | 4/5/1 | 6 M |
| UKA | 10 | 64 ± 5 | 6/4 | 2/4/4 | 12 M | |||||
| Jefferson 1989 | Prospective | CWHTO/MB | HTO | 23(20 patients) | 57(31–73) | NC | NC | NC | NC | |
| UKA | 19(15 patients) | 64(55–74) | NC | |||||||
| Broughton 1986 | Retrospective | CWHTO/FB | HTO | 49(45 patients) | 63 | NC | NC | K–L grade | 3.3 | 7.8 ± 1.5 Y |
| UKA | 42(34 patients) | 71 | 3.2 | 5.8 ± 1.2 Y | ||||||